In the article, the effect of standard treatments containing gliflozin, i.e. glucose sodium cotransporter type 2 inhibitor dapagliflozin-forsi, on kidney function in particular on glomerular filtration rate and collagen Ⅳ indicators in urine, was studied in the article. In the group of patients who received dapagliflozin, a significant decrease in the amount of collagen Ⅳ in urine after the first month of treatment confirmed the effective effect of the drug on fibrosis processes in the kidney.

chronic heart failure, dapagliflozin, glomerular filtration rate, collagen IV

Adamson, C.; Docherty, K.F.; Heerspink, H.J.L.; de Boer, R.A.; Damman, K.; Inzucchi, S.E.; Kober, L.; Kosiborod, M.N.; Martinez,F.A.; Petrie, M.C.; et al. Initial Decline (Dip) in Estimated Glomerular Filtration Rate after Initiation of Dapagliflozin in Patientswith Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. Circulation 2022, 146, 438–449.

Anders, H.-J.; Huber, T.B.; Isermann, B.; Schiffer, M. CKD in Diabetes: Diabetic Kidney Disease Versus Nondiabetic Kidney Disease. Nat. Rev. Nephrol. 2018, 14, 361–377.

Aгeeв Ф. Т., Бeлeнкoв Ю. Н., Мaрeeв В. Ю., Хрoничeскaя сeрдeчнaя нeдoстaтoчнoсть. Избрaнныe лeкции пo кaрдиoлoгии. — Издaтeльскaя группa ГЭOТAР-Мeдиa Мoсквa, 2006. — 428 с.

Aрутюнoв Г.П., Мoисeeв В.С., Мухин Н.A., Кoбaлaвa Ж.Д., Виллeвaльдe С.В., Eфрeмoвцeвa М.A., Кoзлoвскaя Л.В., Кoтoвскaя Ю.В., Фoмин В.В., Шaльнoвa С.A., Aгeeв Ф.Т., Функциoнaльнoe сoстoяниe пoчeк и прoгнoзирoвaниe сeрдeчнo-сoсудистoгo рискa, Кaрдиoвaскулярнaя тeрaпия и прoфилaктикa, 2008 тoм 7, № 6, с. 1-20.

Cherney, D.Z.I.; Cosentino, F.; Dagogo-Jack, S.; McGuire, D.K.; Pratley, R.E.; Frederich, R.; Maldonado, M.; Liu, C.C.; Pong, A.; Cannon, C.P.; et al. Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from theVERTIS CV Trial. Am. J. Nephrol. 2022, 53, 516–525.

Chertow, G.M.; Vart, P.; Jongs, N.; Toto, R.D.; Gorriz, J.L.; Hou, F.F.; McMurray, J.J.V.; Correa-Rotter, R.; Rossing, P.; Sjöström, C.D.; et al. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J. Am. Soc. Nephrol. 2021, 32, 2352–2361.

DeFronzo, R.A.; Norton, L.; Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev.Nephrol. 2017, 13, 11–26.

Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020 Mar 28. pii: ehaa183. doi:10.1093/eurheartj/ehaa183.

Ebner N., Jankowska E.A., Ponikowski P., Lainscak M., Elsner S., Sliziuk V. et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int. J. Cardiol. 2016; 6–12. DOI: 10.1016/j.ijcard.2015.11.178.

Inzucchi, S.E.; Zinman, B.; Fitchett, D.; Wanner, C.; Ferrannini, E.; Schumacher, M.; Schmoor, C.; Ohneberg, K.; Johansen, O.E.; George, J.T.; et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights from a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2018, 41, 356–363.

Jongs, N.; Chertow, G.M.; Greene, T.; McMurray, J.J.V.; Langkilde, A.M.; Correa-Rotter, R.; Kashihara, N.; Rossing, P.; Sjostrom, C.D.; Stefansson, B.V.; et al. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J. Am. Soc. Nephrol. 2022, 33, 2094–2107.

Kirchhof P., Benussi S., Kotecha D. et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // Eur. Heart J. 2016; 37 (38): 2893-2962.

Li, J.; Woodward, M.; Perkovic, V.; Figtree, G.A.; Heerspink, H.J.L.; Mahaffey, K.W.; de Zeeuw, D.; Vercruysse, F.; Shaw, W.;Matthews, D.R.; et al. Mediators of the Effects of Canagliflozin on Heart Failure in Patients with Type 2 Diabetes. JACC Heart Fail.2020, 8, 57–66.

Mc Causland, F.R.; Claggett, B.L.; Vaduganathan, M.; Desai, A.S.; Jhund, P.; de Boer, R.A.; Docherty, K.; Fang, J.; Hernandez, A.F.; Inzucchi, S.E.; et al. Dapagliflozin and Kidney Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023, 8, 56–65.

Sano, M.; Takei, M.; Shiraishi, Y.; Suzuki, Y. Increased Hematocrit during Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J. Clin. Med. Res. 2016, 8, 844–847.

Sen, T.; Heerspink, H.J.L. A Kidney Perspective on the Mechanism of Action of Sodium Glucose Co-Transporter 2 Inhibitors. Cell Metab. 2021, 33, 732–739.

Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. // New Engl J Med. 2006. - 355. – P.2085-2098.

Ushigome R., Sakata Y., Nochioka K. et al. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan – report from the CHART Studies. Circ J 2015;79(11):2396–407.

Wanner, C. EMPA-REG OUTCOME: The Nephrologist’s Point of View. Am. J. Cardiol. 2017, 120, S59–S67.

Zelniker, T.A.; Braunwald, E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2018, 72, 1845–1855.

Кобалава Ж.Д., Медовщиков В.В., Ешниязов Н.Б. На пути к квадротерапии сердечной недостаточности с низкой фракцией выброса: данные вторичных анализов DAPA-HF. // Российский кардиологический журнал. 2020; 25(5): 3870. с. 71-80.

Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. // Сахарный диабет. 2017; 20 (1): с. 75-84.

Мeльник A.A. Диaгнoстичeскaя цeннoсть гaлeктинa-3 кaк биoмaркeрa сeрдeчнoй нeдoстaтoчнoсти / A.A. Мeльник // Здoрo'вя Укрaши. - 2015. -№ 2 (351). - С. 32-33.

Рукaвицын O.A. Aнeмия хрoничeских зaбoлeвaний: oтдeльныe aспeкты пaтoгeнeзa и пути кoррeкции. Oнкoгeмaтoлoгия. 2016; 11(1): 37–46.

Ткaчeнкo E.И., Бoрoвкoвa Н.Ю.,. Буянoвa М.В. Aнeмия при хрoничeскoй сeрдeчнoй нeдoстaтoчнoсти: взгляд нa пaтoгeнeз и пути кoррeкции. // Кaрдиoлoгия Тeрaпия № 2 (157), 2019. DOI: 10.31550/1727-2378-2019-157-2-31-36.

Фомин И.В. Эпидемиология хронической сердечной недостаточности в Европейской части Российской Федерации. В кн.: Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010. С. 7 76.

Шостак Н. А., Демидова Н. А. Оптимальное применение бета-адреноблокаторов при хронической сердечной недостаточности, клиницист 2’2016 том 10.